Anoscope Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The anthracycline market size has grown strongly in recent years. It will grow from $1.52 billion in 2024 to $1.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rising prevalence of cancer, growing demand for personalized cancer treatment, rising awareness of the benefits of anthracyclines, investment in anthracycline.

The anthracycline market size is expected to see strong growth in the next few years. It will grow to $2.13 billion in 2029 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to growing awareness about cancer treatment, investments in research and development for cancer treatments, growing demand for effective and convenient treatments for cancer, growing number of screening programs for cancer, government initiatives. Major trends in the forecast period include advancements in anthracycline formulations, combination therapies, cardioprotective strategies, developing biosimilars of anthracyclines.

The burgeoning prevalence of cancer is poised to act as a major catalyst for the future growth of the anthracycline market. Cancer, a group of disorders characterized by the unbridled proliferation of abnormal cells that can manifest in virtually any organ or tissue within the body, often transcending their typical boundaries and potentially spreading to other body parts or invading neighboring tissues. In this landscape, anthracyclines, a class of potent chemotherapy drugs, assume a crucial role in cancer treatment. They achieve this by impeding cell division through the disruption of DNA structure, effectively terminating its normal function. For instance, as of 2023, data from the American Cancer Society Inc., a US-based nonprofit health organization, projects a rise in new cancer cases with an estimated 1.9 million diagnoses in the United States. This marks an increase from the 1.8 million new cancer cases diagnosed in 2020. Furthermore, the anticipated figures for cancer-related deaths in 2023 stand at approximately 609,820, compared to the expected 606,520 in 2020. Consequently, the mounting incidence of cancer is the driving force behind the burgeoning anthracycline market.

The anthracycline market is primed for substantial growth in the foreseeable future, primarily attributed to the escalating adoption of personalized medicine. Personalized medicine, often referred to as precision medicine, represents a niche within medical treatment characterized by tailoring therapeutic approaches to the unique attributes of individual patients. This level of customization takes into account the genetic, molecular, and specific disease characteristics of patients, allowing for the precise integration of anthracycline chemotherapy drugs in combination with targeted therapies. The result is the delivery of more effective and less harmful treatment strategies.For instance, as of October 2022, reports from STAT, a US-based health-focused news entity, revealed that there are in excess of 75,000 genetic testing products and 300 personalized medicines in existence. Furthermore, data from the Personalized Medicine Coalition, a representative organization based in the United States, indicated that in 2022, the FDA approved personalized medicines for 34% of newly developed drugs. This trend has been consistent over the preceding eight years, with at least 25% of new drugs receiving approval as personalized medicines. Consequently, the escalating demand for personalized medicine stands as the driving force behind the expansion of the anthracycline market.

Leading companies in the anthracycline market are focusing on developing innovative products, such as non-cardiotoxic formulations, to enhance the safety of chemotherapy treatments. Non-cardiotoxic formulations are designed to minimize or eliminate damage to the heart, addressing the harmful effects typically associated with certain chemotherapy drugs, like anthracyclines, which can lead to heart failure or other cardiac issues. For example, in April 2024, the European Medicines Agency (EMA) granted Orphan Drug Designation to Annamycin, a next-generation anthracycline, for the treatment of acute myeloid leukemia (AML). This designation provides significant incentives for developing treatments for rare diseases, including seven years of market exclusivity post-approval, preventing other manufacturers from marketing the same drug for the same indication. Additionally, the designation offers tax credits covering up to 50% of clinical trial costs, application fee waivers, and regulatory support from the FDA, helping to alleviate the financial burden of developing drugs for small patient populations.

In August 2023, CNX Therapeutics Limited, a UK-based specialty pharmaceutical company, acquired four cancer support products - Cardioxane (dexrazoxane), Savene (dexrazoxane), Totect (dexrazoxane), and Ethyol (amifostine) - from Clinigen Limited for an undisclosed amount. Cardioxane is used in adults with advanced or metastatic breast cancer to prevent long-term cardiac damage caused by certain anthracyclines. Savene treats anthracycline extravasation, a rare condition in cancer patients, while Totect addresses both anthracycline extravasation and cardiovascular prevention related to doxorubicin in women with metastatic breast cancer. This acquisition strengthens CNX Therapeutics' portfolio of essential hospital products, broadening its established presence in over 40 countries and unlocking new opportunities across multiple global markets. Clinigen Limited is a UK-based pharmaceutical services company that provides commercial medicines for clinical study use.

Major companies operating in the anthracycline market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Fresenius SE & Co. KGaA, Merck & Co. Inc., Gilead Sciences Inc., Zydus Lifesciences Limited, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Gland Pharma Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Endo Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Accord Healthcare Limited, Athenex Inc., Miracalus Pharma Pvt. Ltd., Transo-Pharm Usa LLC, BluePoint Laboratories, Areva Pharmaceuticals Inc., GeneraMedix Inc., Salius Pharma Pvt. Ltd.

Asia-Pacific was the largest region in the anthracycline market in 2024. The regions covered in anthracycline report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anthracycline market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The anthracycline market consists of sales of aclarubicin and pixantrone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Anthracyclines represent a class of potent chemotherapy drugs derived from specific Streptomyces bacteria strains. These drugs exert their therapeutic action by disrupting the DNA (deoxyribonucleic acid) within cancer cells, effectively impeding their growth and replication. Anthracyclines find application in the treatment of a range of cancer types, including but not limited to breast cancer, various lymphomas, leukemia, and more.

The primary anthracycline drugs encompass daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin. Daunorubicin, for instance, serves as an anthracycline chemotherapy agent that operates by hindering the synthesis of both DNA and RNA. This inhibition is achieved through the intercalation of daunorubicin into the DNA helix, coupled with the inhibition of topoisomerase II. This dual mechanism results in cell cycle arrest and the induction of apoptosis, particularly in rapidly dividing cells. Anthracycline drugs are available in various formulations, including powders, capsules, solutions, injections, suspensions, and others. These formulations serve multiple therapeutic applications, addressing conditions such as acute lymphocytic leukemia, acute myelogenous leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, bladder cancer, breast cancer, and more. The diverse array of end users for these medications includes hospitals, home care settings, specialty clinics, and others.

The anthracycline market research report is one of a series of new reports that provides anthracycline market statistics, including anthracycline industry global market size, regional shares, competitors with an anthracycline market share, detailed anthracycline market segments, market trends and opportunities and any further data you may need to thrive in the anthracycline industry. This anthracycline market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.